NF-E2-Related Factor 2 Suppresses Intestinal Fibrosis by Inhibiting Reactive Oxygen Species-Dependent TGF-β1/SMADs Pathway
Overview
Affiliations
Background And Aims: This study aimed to evaluate the antifibrotic effects of NF-E2-Related Factor 2 (Nrf2) on intestinal fibrosis. Intestinal fibrosis is a common complication of Crohn's disease; however, its mechanism of intestinal fibrosis is largely unclear.
Methods: BALB/c mice received 2,4,6-trinitrobenzene sulfonic acid weekly via intrarectal injections to induce chronic fibrotic colitis. They also diet containing received 1% (w/w) tert-butylhydroquinone (tBHQ), which is an agonist of Nrf2. Human intestinal fibroblasts (CCD-18Co cells) were pretreated with tBHQ or si-Nrf2 followed by stimulation with transforming growth factor-β1 (TGF-β1), which transformed the cells into myofibroblasts. The main fibrosis markers such as α-smooth muscle actin, collagen I, tissue inhibitor of metalloproteinase-1, and TGF-β1/SMADs signaling pathway were detected by quantitative real-time RT-PCR, immunohistochemical analysis, and Western blot analysis. Levels of cellular reactive oxygen species (ROS) were detected by dichlorodihydrofluorescein diacetate.
Results: tBHQ suppressed the intestinal fibrosis through the TGF-β1/SMADs signaling pathway in TNBS-induced colitis and CCD-18Co cells. Moreover, Nrf2 knockdown enhanced the TGF-β1-induced differentiation of CCD-18Co cells. ROS significantly increased in TGF-β1-stimulated CCD-18Co cells. Pretreatment with HO, the primary component of ROS, was demonstrated to block the effect of tBHQ on reducing the expression of TGF-β1. Moreover, scavenging ROS by N-acetyl cysteine could inhibit the increasing expression of TGF-β1 promoted by Nrf2 knockdown.
Conclusions: The results suggested that Nrf2 suppressed intestinal fibrosis by inhibiting ROS/TGF-β1/SMADs pathway in vivo and in vitro.
Mechanism of Action and Therapeutic Implications of Nrf2/HO-1 in Inflammatory Bowel Disease.
Yuan L, Wang Y, Li N, Yang X, Sun X, Tian H Antioxidants (Basel). 2024; 13(8).
PMID: 39199256 PMC: 11351392. DOI: 10.3390/antiox13081012.
Inflammation accelerating intestinal fibrosis: from mechanism to clinic.
Xin S, Liu X, He C, Gao H, Wang B, Hua R Eur J Med Res. 2024; 29(1):335.
PMID: 38890719 PMC: 11184829. DOI: 10.1186/s40001-024-01932-2.
Mustafa Badi R, Khaleel E, Satti H, Monir R J Tradit Complement Med. 2024; 14(2):203-214.
PMID: 38481546 PMC: 10927380. DOI: 10.1016/j.jtcme.2023.11.003.
Preventing fibrosis in IBD: update on immune pathways and clinical strategies.
Wang J, Yang B, Chandra J, Ivanov A, Brown J, Rieder F Expert Rev Clin Immunol. 2024; 20(7):727-734.
PMID: 38475672 PMC: 11180587. DOI: 10.1080/1744666X.2024.2330604.
The role of Nrf2 in the pathogenesis and treatment of ulcerative colitis.
Peng S, Shen L, Yu X, Zhang L, Xu K, Xia Y Front Immunol. 2023; 14:1200111.
PMID: 37359553 PMC: 10285877. DOI: 10.3389/fimmu.2023.1200111.